Professor Richard Adams
B.Med.Sci, BM BS, MRCP, FRCR, MD
Director of Cancer Trials, Director of the Wales Cancer Bank, Translational Research Lead for Solid Cancer Clinical Trials
- adamsra3@cardiff.ac.uk
- 6th Floor, Neuadd Meirionnydd, University Hospital of Wales, Heath Park, Cardiff, CF14 4YS
- Available for postgraduate supervision
Overview
Richard Adams is Professor and Honorary Consultant Clinical Oncologist at Cardiff University and Velindre Cancer Centre. He is Director of Cancer Trials for the Centre for Trials Research and clinical Director of the Wales Cancer Bank. His clinical practice and research is focused on lower gastrointestinal cancers. He is chair of the National Cancer Research Institute CTRad WS2 (UK radiotherapy research) subgroup and the Clinical Expert Review Panel for CRUK. He is active in national and international research organisations including IRCI the International Rare Cancer Initiative (for anal cancer) and ARCAD (for metastatic colorectal cancer).
Richard chairs the biomarker development group for the UK phase III FOCUS4 trial in metastatic colorectal cancer and is Chief investigator for the FOCUS4 D and N trials. He leads on the radiotherapy quality assurance programme for the UK rectal cancer trials. He has a role within Wales to engage researchers in cancer clinical research . He oversees collaborative translational research in numerous phase II/ III colorectal cancer trials. He was a founder member of and now chairs the South Wales Sierra Leone Cancer Care link.
Biography
Richard Adams is Professor and Honorary Consultant Clinical Oncologist at Cardiff University and Velindre Cancer Centre. He is Director of Cancer Trials for the Centre for Trials Research and clinical Director of the Wales Cancer Bank. His clinical practice and research is focused on lower gastrointestinal cancers. He is chair of the National Cancer Research Institute CTRad WS2 (UK radiotherapy research) subgroup and the Clinical Expert Review Panel for CRUK. He is active in national and international research organisations including IRCI the International Rare Cancer Initiative (for anal cancer) and ARCAD (for metastatic colorectal cancer).
Richard chairs the biomarker development group for the UK phase III FOCUS4 trial in metastatic colorectal cancer and is Chief investigator for the FOCUS4 D and N trials. He leads on the radiotherapy quality assurance programme for the UK rectal cancer trials. He has a role within Wales to engage researchers in cancer clinical research . He oversees collaborative translational research in numerous phase II/ III colorectal cancer trials. He was a founder member of and now chairs the South Wales Sierra Leone Cancer Care link.
Professional memberships
- Chair Ano-rectal subgroup of the National Cancer Research Institute clinical study group (CSG) 2012 – onwards
- International Executive board member ARCAD Advanced Colorectal cancer database international research group and UK member 2011-present
- International Rare Cancer Initiative Anal Cancer Group member 2011-present
- Lead for radiotherapy Quality Assurance for ARISTOTLE/COPERNICUS and TREC trials 2011-present
- NCRI Colorectal cancer Clinical Studies Group (CSG) member 2010-present
- National Cancer Research Institute CTRad CSG phase I/II subgroup chair 2014-presetn
- ESMO scientific committee lower gastrointestinal cancers 2014- present
- ASCO - member
Academic positions
2017-present: Professor in Cancer Clinical trials Cardiff University
2013-2017: Reader in Clinical Oncology Cardiff University
2007-2013: Senior Lecturer in Clinical Oncology Cardiff University
2007-present: Honorary Consultant in Clinical Oncology Velindre NHS Trust
2007-present: Honorary Consultant in Clinical Oncology Cardiff and Vale University Health Board
Publications
Teaching
I have been a long term educationalist at undergraduate, post graduate and peer levels.
I reguarly deliver lectures at national and international meetings
Development and delivery of cancer clinical trials, with a view to using the best science through collaborative team work to answer questions and change practice relevant to patients, diagnosed with cancer